Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial
Catherine G. Ireland(Brigham and Women's Hospital), Carolyn Y. Ho(Brigham and Women's Hospital), Anna Axelsson Raja(Copenhagen University Hospital), Brian Claggett(National Heart Lung and Blood Institute), Ivan Wilmot(Cincinnati Children's Hospital Medical Center), Joseph W. Rossano(Children's Hospital of Philadelphia), Alexandre C. Pereira(University of Washington), E. John Orav(Mass General Brigham), Anjali Owens(University of Pennsylvania), Amit R. Patel(University of Chicago Medical Center), Jonathan H. Soslow(Vanderbilt University Medical Center), Henning Bundgaard, Matthew T. Wheeler(Stanford University), Kimberly Y. Lin(Children's Hospital of Philadelphia), Kenneth Zahka(Cleveland Clinic), Jason R. Becker(Vanderbilt University), Matthew R.G. Taylor(University of Colorado Anschutz Medical Campus), Luisa Mestroni(University of Colorado Anschutz Medical Campus), Danielle S. Burstein(Children's Hospital of Philadelphia), Ilya Giverts(Massachusetts General Hospital), Sharlene M. Day(Cardiovascular Institute of the South), Richard G. Bach(Washington University in St. Louis), Mark W. Russell(University of Michigan), Charles E. Canter
Cited by 6
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
|Circulation|2014|1k
Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands
|Nature Genetics|2017|927